RET rechallenge following disease progression demonstrated greater efficacy with select combination therapies targeting bypass resistance vs single agents.

Revisit key updates from the ASCO Annual Meeting, the FDA, NCCN, and more.

The photosensitizing drug and light delivery system yielded complete responses and a low rate of disease recurrence in patients with low-grade UTUC.

Perioperative sacituzumab govitecan-hziy plus pembrolizumab was safe and active in muscle-invasive bladder cancer.

Tess O’Meara, MD, discusses the implications of data from the DESTINY-Breast09 trial of first-line T-DXd plus pertuzumab in HER2-positive breast cancer.

Jason Luke, MD, discusses IMA203 vs investigator’s choice of standard therapy in patients with previously treated advanced cutaneous melanoma.

Elizabeth Mittendorf, MD, PhD, MHCM, discusses advancing ASCO’s mission through research advocacy, global collaboration, and a commitment to equity.

Time-limited therapy with acalabrutinib plus venetoclax with or without obinutuzumab is approved in the European Union for untreated patients with CLL.

The FDA received an NDA for vepdegestrant in ER-positive, HER2-negative advanced breast cancer with an ESR1 mutation.

Hope Rugo, MD, discusses the application of findings from the DESTINY-Breast09 trial of T-DXd plus pertuzumab in HER2-positive breast cancer.

Hope Rugo, MD, discusses the evolving use of antibody-drug conjugates in HER2-positive breast cancer.

Nitin Jain, MD, discusses the role pirtobrutinib has played in the chronic lymphocytic leukemia treatment paradigm.

Experts highlight key abstracts to watch for at the 2025 EHA Congress.

Panelists discuss the CABINET trial’s safety findings, noting that while cabozantinib showed a manageable toxicity profile similar to other cancers, its use in heavily pretreated neuroendocrine tumor patients—especially post peptide receptor […]

Panelists discuss how the accelerated approval of trastuzumab deruxtecan (T-DXd) offers a promising new treatment option for patients with HER2-positive gynecologic cancers, while highlighting the need for confirmatory trials to refine patient […]

RP1/nivolumab generated responses in deep/visceral lesions and in non-injected lesions in advanced PD-1–refractory melanoma.

Panelists discuss the CABINET trial’s findings that cabozantinib significantly improved progression-free survival in both pancreatic and extrapancreatic neuroendocrine tumors, highlighting its efficacy in a heavily pretreated, real-world […]

Panelists discuss how the recent accelerated approval of trastuzumab deruxtecan (T-DXd) in HER2-expressing endometrial cancer prompts critical questions about treatment sequencing, as clinicians weigh efficacy, toxicity, and emerging evidence to […]

Erica L. Mayer, MD, MPH, discusses ESR1 mutation detection by ctDNA liquid biopsy in the phase 3 SERENA-6 study.

Sara M. Tolaney, MD, MPH, details the clinical implications for first-line T-DXd/pertuzumab for the treatment of patients with HER2-positive breast cancer.